trending Market Intelligence /marketintelligence/en/news-insights/trending/qoidrlhl1sx7-il9yldy6w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Sun Pharma to acquire Novartis cancer drug Odomzo for $175M

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Sun Pharma to acquire Novartis cancer drug Odomzo for $175M

India's Sun Pharmaceutical Industries Ltd. agreed to buy Novartis AG's oncology drug Odomzo for an upfront payment of $175 million plus future milestone payments.

The agreement, which was signed between units of both parties, is subject to antitrust clearance and other closing conditions.

Odomzo, which received FDA approval in July 2015, is used to treat adult patients with locally advanced basal cell carcinoma that recurred after surgery or radiation therapy, or those who are not qualified for surgery or radiation therapy.

Sun Pharma said that the acquisition will support its expansion into branded oncology, adding that the drug has global potential. Odomzo has marketing approval in more than 30 countries.